



April 26, 2016

Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016

WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 16, 2016 to discuss the company's financial results and provide a general business update.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Domestic Dial-in Number: (855) 238-6664

International Dial-in Number: (262) 912-4798

Conference ID: 89304739

Live Webcast: <http://edge.media-server.com/m/p/msy6sdt8>

For those unable to participate in the conference call or webcast, a live audio webcast of the call will also be available on the Investors section of the Company's website, www.syndax.com, and a webcast replay will be available there for 30 days.

About Syndax Pharmaceuticals, Inc.

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer. Concurrently, Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. For more information on Syndax please visit www.syndax.com.

Investor and Media Contacts

Barbara Ryan
bryan@syndax.com
(646) 690-7639